Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Immuneering CorpIMRX · Entity 5884 | Director · PRESIDENT AND CEO | June 23, 2026 | June 24, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Immuneering Corp
Report date June 23, 2026 · Filed June 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 2,315,252 |
Reported balance
After 2026-06-23 transaction · row 1
1 source rowRow 1 · 2026-06-23 · Purchase · Acquired 2,400 · Balance 2,315,252 F1: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $4.55 to $4.59. The price reported in this column reflects the weighted average purchase price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares acquired at each price. |
| Class A Common StockSEC Table I · non-derivative | IndirectSee Foonote | 894,927 |
Reported balance
Holding disclosure · report date 2026-06-23 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 894,927 F2: Held by the Benjamin J. Zeskind 2020 Family Trust, where Lisa Schwartz, Dr. Zeskind's spouse, serves as sole trustee. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $4.55 to $4.59. The price reported in this column reflects the weighted average purchase price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares acquired at each price.
F2: Held by the Benjamin J. Zeskind 2020 Family Trust, where Lisa Schwartz, Dr. Zeskind's spouse, serves as sole trustee.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 23, 2026 Filed Jun 24, 2026 20:11 UTC | Immuneering Corp IMRX · Entity 5884 | PurchaseClass A Common Stock | 2,400 | $4.56 | $10,948.08 |
DisclosureSEC source: 0001790340-26-000078 · wk-form4_1782331885.xml · nonDerivative · entry 1 Zeskind Benjamin J. · CIK 0001870062 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,315,252 F1 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $4.55 to $4.59. The price reported in this column reflects the weighted average purchase price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares acquired at each price. Read SEC document |
| February 03, 2026 Filed Feb 5, 2026 13:10 UTC | Immuneering Corp IMRX · Entity 5884 | GrantStock Option · Derivative | 688,000 | $0.00 Strike: $4.91 | $0.00 |
DisclosureSEC source: 0001790340-26-000022 · wk-form4_1770297015.xml · derivative · entry 1 Zeskind Benjamin J. · CIK 0001870062 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 688,000 Underlying: Class A Common Stock · 688,000 shares Expires 2036-02-03 F1 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on February 1, 2026, and will be fully vested and exercisable on January 1, 2030. Read SEC document |
| July 02, 2025 Filed Jul 3, 2025 13:12 UTC | Immuneering Corp IMRX · Entity 5884 | PurchaseClass A Common Stock | 7,015 | $3.53 | $24,792.41 |
DisclosureSEC source: 0001790340-25-000094 · wk-form4_1751548321.xml · nonDerivative · entry 2 Zeskind Benjamin J. · CIK 0001870062 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,312,852 F2 · balance_after: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $3.45 to $3.64. The price reported in this column reflects the weighted average purchase price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares acquired at each price. Read SEC document |
| July 01, 2025 Filed Jul 3, 2025 13:12 UTC | Immuneering Corp IMRX · Entity 5884 | PurchaseClass A Common Stock | 2,985 | $3.38 | $10,086.91 |
DisclosureSEC source: 0001790340-25-000094 · wk-form4_1751548321.xml · nonDerivative · entry 1 Zeskind Benjamin J. · CIK 0001870062 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,305,837 F1 · balance_after: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $3.35 to $3.41. The price reported in this column reflects the weighted average purchase price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares acquired at each price. Read SEC document |
| June 18, 2025 Filed Jun 20, 2025 13:09 UTC | Immuneering Corp IMRX · Entity 5884 | PurchaseClass A Common Stock | 21,000 | $2.39 | $50,143.80 |
DisclosureSEC source: 0001790340-25-000081 · wk-form4_1750424967.xml · nonDerivative · entry 1 Zeskind Benjamin J. · CIK 0001870062 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,302,852 F1 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $2.31 to $2.44. The price reported in this column reflects the weighted average purchase price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares acquired at each price. Read SEC document |
| February 05, 2025 Filed Feb 7, 2025 21:10 UTC | Immuneering Corp IMRX · Entity 5884 | GrantStock Option · Derivative | 480,000 | $0.00 Strike: $1.91 | $0.00 |
DisclosureSEC source: 0001790340-25-000024 · wk-form4_1738962616.xml · derivative · entry 1 Zeskind Benjamin J. · CIK 0001870062 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 480,000 Underlying: Class A Common Stock · 480,000 shares Expires 2035-02-05 F1 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on February 1, 2025, and will be fully vested and exercisable on January 1, 2029. Read SEC document |
| March 19, 2024 Filed Mar 19, 2024 22:59 UTC | Immuneering Corp IMRX · Entity 5884 | PurchaseClass A Common Stock | 20,000 | $2.77 | $55,326.00 |
DisclosureSEC source: 0001790340-24-000026 · wk-form4_1710889187.xml · nonDerivative · entry 1 Zeskind Benjamin J. · CIK 0001870062 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,281,852 F1 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $2.54 to $2.95. The price reported in this column reflects the weighted average purchase price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares acquired at each price. Read SEC document |
| February 08, 2024 Filed Feb 9, 2024 21:07 UTC | Immuneering Corp IMRX · Entity 5884 | GrantStock Option · Derivative | 16,414 | $0.00 Strike: $6.70 | $0.00 |
DisclosureSEC source: 0001790340-24-000006 · wk-form4_1707512827.xml · derivative · entry 2 Zeskind Benjamin J. · CIK 0001870062 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,414 Underlying: Class A Common Stock · 16,414 shares Expires 2029-02-08 F1 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on February 1, 2024, and will be fully vested and exercisable on January 1, 2028. Read SEC document |
| February 08, 2024 Filed Feb 9, 2024 21:07 UTC | Immuneering Corp IMRX · Entity 5884 | GrantStock Option · Derivative | 244,286 | $0.00 Strike: $6.09 | $0.00 |
DisclosureSEC source: 0001790340-24-000006 · wk-form4_1707512827.xml · derivative · entry 1 Zeskind Benjamin J. · CIK 0001870062 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 244,286 Underlying: Class A Common Stock · 244,286 shares Expires 2034-02-08 F1 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on February 1, 2024, and will be fully vested and exercisable on January 1, 2028. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 21:16 UTC | Immuneering Corp IMRX · Entity 5884 | GrantStock Option · Derivative | 21,756 | $0.00 Strike: $4.68 | $0.00 |
DisclosureSEC source: 0001415889-23-002757 · form4-02172023_040220.xml · derivative · entry 2 Zeskind Benjamin J. · CIK 0001870062 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 374,000 Underlying: Class A Common Stock · 21,756 shares Expires 2028-02-15 F2 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on February 1, 2023, and will be fully vested and exercisable on January 1, 2027. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 21:16 UTC | Immuneering Corp IMRX · Entity 5884 | GrantStock Option · Derivative | 352,244 | $0.00 Strike: $4.25 | $0.00 |
DisclosureSEC source: 0001415889-23-002757 · form4-02172023_040220.xml · derivative · entry 1 Zeskind Benjamin J. · CIK 0001870062 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 352,244 Underlying: Class A Common Stock · 352,244 shares Expires 2033-02-15 F1 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on February 1, 2023, and will be fully vested and exercisable on January 1, 2027. Read SEC document |
| December 22, 2022 Filed Dec 27, 2022 13:14 UTC | Immuneering Corp IMRX · Entity 5884 | Exercise / conversionStock Option · Derivative | 2,500 | $0.00 Strike: $3.01 | $0.00 |
DisclosureSEC source: 0001415889-22-012975 · form4-12272022_011215.xml · derivative · entry 3 Zeskind Benjamin J. · CIK 0001870062 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 203,500 Underlying: Class A Common Stock · 2,500 shares Expires 2029-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option has fully vested and is currently exercisable. Read SEC document |
| December 22, 2022 Filed Dec 27, 2022 13:14 UTC | Immuneering Corp IMRX · Entity 5884 | Exercise / conversionClass A Common Stock | 2,500 | $3.01 | $7,525.00 |
DisclosureSEC source: 0001415889-22-012975 · form4-12272022_011215.xml · nonDerivative · entry 1 Zeskind Benjamin J. · CIK 0001870062 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,261,852 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 12, 2022 Filed Apr 14, 2022 20:30 UTC | Immuneering Corp IMRX · Entity 5884 | Exercise / conversionStock Option · Derivative | 2,000 | $0.00 Strike: $3.01 | $0.00 |
DisclosureSEC source: 0001415889-22-004065 · form4-04142022_010428.xml · derivative · entry 3 Zeskind Benjamin J. · CIK 0001870062 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 206,000 Underlying: Class A Common Stock · 2,000 shares Expires 2029-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option has fully vested and is currently exercisable. Read SEC document |
| April 12, 2022 Filed Apr 14, 2022 20:30 UTC | Immuneering Corp IMRX · Entity 5884 | Exercise / conversionClass A Common Stock | 2,000 | $3.01 | $6,020.00 |
DisclosureSEC source: 0001415889-22-004065 · form4-04142022_010428.xml · nonDerivative · entry 1 Zeskind Benjamin J. · CIK 0001870062 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,259,352 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 23, 2022 Filed Mar 24, 2022 20:39 UTC | Immuneering Corp IMRX · Entity 5884 | PurchaseClass A Common Stock | 3,000 | $8.02 | $24,060.00 |
DisclosureSEC source: 0001415889-22-003324 · form4-03242022_010305.xml · nonDerivative · entry 1 Zeskind Benjamin J. · CIK 0001870062 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,257,352 F1 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $7.92 to $8.10. The price reported in this column reflects the weighted average purchase price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares acquired at each price. Read SEC document |
| February 28, 2022 Filed Mar 1, 2022 22:19 UTC | Immuneering Corp IMRX · Entity 5884 | Exercise / conversionStock Option · Derivative | 2,000 | $0.00 Strike: $3.01 | $0.00 |
DisclosureSEC source: 0001415889-22-002061 · form4-03012022_020328.xml · derivative · entry 3 Zeskind Benjamin J. · CIK 0001870062 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 208,000 Underlying: Class A Common Stock · 2,000 shares Expires 2029-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option has fully vested and is currently exercisable. Read SEC document |
| February 28, 2022 Filed Mar 1, 2022 22:19 UTC | Immuneering Corp IMRX · Entity 5884 | Exercise / conversionClass A Common Stock | 2,000 | $3.01 | $6,020.00 |
DisclosureSEC source: 0001415889-22-002061 · form4-03012022_020328.xml · nonDerivative · entry 1 Zeskind Benjamin J. · CIK 0001870062 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,254,352 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 10, 2022 Filed Feb 14, 2022 22:27 UTC | Immuneering Corp IMRX · Entity 5884 | GrantStock Option · Derivative | 45,615 | $0.00 Strike: $10.63 | $0.00 |
DisclosureSEC source: 0001415889-22-001324 · form4-02142022_020219.xml · derivative · entry 2 Zeskind Benjamin J. · CIK 0001870062 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,100 Underlying: Class A Common Stock · 45,615 shares Expires 2027-02-09 F2 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on February 1, 2022, and will be fully vested and exercisable on January 1, 2026. Read SEC document |
| February 10, 2022 Filed Feb 14, 2022 22:27 UTC | Immuneering Corp IMRX · Entity 5884 | GrantStock Option · Derivative | 156,485 | $0.00 Strike: $9.66 | $0.00 |
DisclosureSEC source: 0001415889-22-001324 · form4-02142022_020219.xml · derivative · entry 1 Zeskind Benjamin J. · CIK 0001870062 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,485 Underlying: Class A Common Stock · 156,485 shares Expires 2032-02-09 F1 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on February 1, 2022, and will be fully vested and exercisable on January 1, 2026. Read SEC document |
| October 22, 2021 Filed Feb 10, 2022 21:29 UTC | Immuneering Corp IMRX · Entity 5884 | GiftClass A Common Stock | 350,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-001194 · form5-02102022_010236.xml · nonDerivative · entry 2 Zeskind Benjamin J. · CIK 0001870062 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Foonote Disclosed balance after: 894,927 F1 · ownership.nature: Held by the Benjamin J. Zeskind 2020 Family Trust, where Lisa Schwartz, Dr. Zeskind's spouse, serves as sole trustee. Read SEC document |
| October 22, 2021 Filed Feb 10, 2022 21:29 UTC | Immuneering Corp IMRX · Entity 5884 | GiftClass A Common Stock | 350,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-001194 · form5-02102022_010236.xml · nonDerivative · entry 1 Zeskind Benjamin J. · CIK 0001870062 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,252,352 Read SEC document |
| September 13, 2021 Filed Sep 14, 2021 20:47 UTC | Immuneering Corp IMRX · Entity 5884 | PurchaseClass A Common Stock | 2,083 | $22.87 | $47,631.96 |
DisclosureSEC source: 0001415889-21-004382 · form4-09142021_010944.xml · nonDerivative · entry 1 Zeskind Benjamin J. · CIK 0001870062 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,602,352 F1 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $22.41 to $23.375. The price reported in this column reflects the weighted average purchase price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares acquired at each price. Read SEC document |
| August 03, 2021 Filed Aug 4, 2021 10:06 UTC | Immuneering Corp IMRX · Entity 5884 | ConversionSeries B Preferred Stock · Derivative | 8,171 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-099741 · tm2123807-8_4seq1.xml · derivative · entry 5 Zeskind Benjamin J. · CIK 0001870062 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 8,171 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's Class A common stock on a one-for-one basis. F1 · price: Immediately prior to the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's Class A common stock on a one-for-one basis. F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's Class A common stock on a one-for-one basis. F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's Class A common stock on a one-for-one basis. Read SEC document |
| August 03, 2021 Filed Aug 4, 2021 10:06 UTC | Immuneering Corp IMRX · Entity 5884 | ConversionSeries A Preferred Stock · Derivative | 40,928 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-099741 · tm2123807-8_4seq1.xml · derivative · entry 4 Zeskind Benjamin J. · CIK 0001870062 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 40,928 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's Class A common stock on a one-for-one basis. F1 · price: Immediately prior to the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's Class A common stock on a one-for-one basis. F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's Class A common stock on a one-for-one basis. F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's Class A common stock on a one-for-one basis. Read SEC document |
| August 03, 2021 Filed Aug 4, 2021 10:06 UTC | Immuneering Corp IMRX · Entity 5884 | PurchaseClass A Common Stock | 2,098 | $15.00 | $31,470.00 |
DisclosureSEC source: 0001104659-21-099741 · tm2123807-8_4seq1.xml · nonDerivative · entry 2 Zeskind Benjamin J. · CIK 0001870062 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,600,269 Read SEC document |
| August 03, 2021 Filed Aug 4, 2021 10:06 UTC | Immuneering Corp IMRX · Entity 5884 | ConversionClass A Common Stock | 49,099 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-099741 · tm2123807-8_4seq1.xml · nonDerivative · entry 1 Zeskind Benjamin J. · CIK 0001870062 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,598,171 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Immediately prior to the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's Class A common stock on a one-for-one basis. F1 · price: Immediately prior to the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's Class A common stock on a one-for-one basis. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.